School of Biosciences and Biotechnology, University of Camerino, Camerino, Italy.
J Lipid Res. 2011 May;52(5):897-907. doi: 10.1194/jlr.M011817. Epub 2011 Feb 25.
Hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) is the rate-controlling enzyme of cholesterol synthesis, and owing to its biological and pharmacological relevance, researchers have investigated several compounds capable of modulating its activity with the hope of developing new hypocholesterolemic drugs. In particular, polyphenol-rich extracts were extensively tested for their cholesterol-lowering effect as alternatives, or adjuvants, to the conventional statin therapies, but a full understanding of the mechanism of their action has yet to be reached. Our work reports on a detailed kinetic and equilibrium study on the modulation of HMGR by the most-abundant catechin in green tea, epigallocatechin-3-gallate (EGCG). Using a concerted approach involving spectrophotometric, optical biosensor, and chromatographic analyses, molecular docking, and site-directed mutagenesis on the cofactor site of HMGR, we have demonstrated that EGCG potently inhibits the in vitro activity of HMGR (K(i) in the nanomolar range) by competitively binding to the cofactor site of the reductase. Finally, we evaluated the effect of combined EGCG-statin administration.
羟甲基戊二酰辅酶 A 还原酶(HMGR)是胆固醇合成的限速酶,由于其具有生物学和药理学意义,研究人员已经研究了几种能够调节其活性的化合物,希望开发新的降胆固醇药物。特别是富含多酚的提取物被广泛测试其降低胆固醇的作用,作为替代物或辅助物来替代传统的他汀类治疗,但对其作用机制的全面理解尚未达成。我们的工作报告了对绿茶中最丰富的儿茶素表没食子儿茶素没食子酸酯(EGCG)对 HMGR 调节的详细动力学和平衡研究。我们采用协同方法,包括分光光度法、光学生物传感器和色谱分析、分子对接和 HMGR 辅因子位点的定点突变,证明 EGCG 通过与还原酶的辅因子位点竞争性结合,强烈抑制 HMGR 的体外活性(在纳摩尔范围内的 K(i))。最后,我们评估了 EGCG-他汀类药物联合给药的效果。